Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SHR-1802 plus camrelizumab and famitinib in advanced solid tumors
CTR20220125Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1802 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started May 2022; status: terminated.
02
Drugs
SHR-1802
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220125.